| Reporting Organization: | WHO - World Health Organization |
|---|---|
| Total Budget ($CAD): | $ 10,000,000 |
| Timeframe: | February 23, 2017 - December 31, 2017 |
| Status: | Completion |
| Contact Information: | Unspecified |
WHO - World Health Organization
| Sub-Saharan Africa - $ 3,526,000.00 (35.26%) | |
|
|
|
| Southeast Asia - $ 1,333,000.00 (13.33%) | |
|
|
|
| South Asia - $ 1,091,000.00 (10.91%) | |
|
|
|
| Europe - $ 1,000,000.00 (10.00%) | |
|
|
|
| East Asia - $ 970,000.00 (9.70%) | |
|
|
|
| South America - $ 696,000.00 (6.96%) | |
|
|
|
| Central Asia - $ 606,000.00 (6.06%) | |
|
|
|
| North Africa - $ 474,000.00 (4.74%) | |
|
|
|
| Central America - $ 304,000.00 (3.04%) | |
|
|
|
| Infectious & Communicable Diseases (100 %) | |
|
|
|
This project supports the implementation of the Global Polio Eradication Initiative (GPEI)’s Endgame Strategic Plan, which provides a global roadmap to eradicate polio by 2019. Project activities include: (1) working with targeted governments to strengthen oral polio vaccine campaign safety and quality and introduce inactivated polio vaccine into routine immunization systems; (2) providing technical assistance to front-line workers to increase immunization coverage; and (3) working with governments to transition polio assets and infrastructure to broader health goals and national health systems. The GPEI is a partnership between UNICEF, the World Health Organization, the United States Centre for Disease Control and Prevention, Rotary International and the Bill & Melinda Gates Foundation. This project contributes to Canada’s $250 million commitment to polio eradication made at the 2013 Abu Dhabi Global Vaccine Summit.
| Gender and age: | Unspecified |
|---|---|
| Total Direct Population: | Unspecified |
Unspecified
Return to topThe expected outcomes as per the GPEI Strategic Plan include: (1) interruption of wild poliovirus transmission globally and more rapid detection and interruption of any new outbreaks due to vaccine-derived polioviruses; (2) strengthen immunization services in focus countries, introduce inactive polio vaccine (IPV) and withdraw oral polio vaccine type 2 (OPV2) globally; (3) certify the eradication and containment of all wild polioviruses and enhance long-term global security from poliomyelitis; and (4) a plan to ensure polio investments contribute to future health goals, through documentation and transition of lessons learned, processes and assets of the Global Polio Eradication Initiative.
Unspecified
